# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001140361-22-015747
Filing Date
2022-04-25
Accepted
2022-04-25 16:31:30
Documents
3

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | ny20002713x2_defa14a.htm | DEFA14A | 9742
2 |  | ny20002713x2_nc01.jpg | GRAPHIC | 2928979
3 |  | ny20002713x2_nc02.jpg | GRAPHIC | 2507989
| Complete submission text file | 0001140361-22-015747.txt |  | 6085480

Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-23186 | Film No.: 22850081
SIC: 2836 Biological Products, (No Diagnostic Substances)